06 June 2017

Congratulations to GHIT Fund on securing over US$200 Million to its replenishment

The Global Health Innovative Technology Fund (GHIT Fund), which financially supports the Pediatric Praziquantel Consortium, announced last week that it has secured commitments of over US$200 million to its replenishment for its next phase of work. 

GHIT’s funding partners, including the Government of Japan (GOJ), private companies, the Bill & Melinda Gates Foundation, and the Wellcome Trust have committed over US$200 million in a significant vote of confidence in the institution’s work. The new commitment for GHIT’s second phase is double the initial US$100 million investment GHIT received when it was created in 2013. The GOJ will contribute roughly half of the replenishment, with other partners splitting the remaining half.

Leveraging Japan’s historic leadership in global health and innovation, along with the unique technology and knowhow of its domestic and global partners, GHIT invests in R&D projects to develop new medicines, vaccines and diagnostics to address a range of infectious diseases, including HIV/AIDS, malaria, tuberculosis and neglected tropical diseases (NTDs). It is the first public-private partnership of its kind for global health research and development (R&D), involving government, private companies, and private foundations.

For more information, please read the full press release issued by the GHIT Fund on 1 June.